Table 5.
Adjusted HRs and 5-year OS rates (with accompanying CIs) for the 277 patients with refractory or relapsed DLBCL previously treated with rituximab who received relapse treatment in the LYFO database in Denmark, 2000–2015
| Treatment category | N | Events | Person years | Adj. HR (95% CI) | 3-year OS (95% CI) | 5-year OS (95% CI) |
|---|---|---|---|---|---|---|
|
| ||||||
| Non-salvage | 83 | 69 | 173 | 1.00 (ref) | 27% (19%–38%) | 17% (10%–28%) |
| Salvage | 194 | 137 | 509 | 1.88 (0.9–3.9) | 39% (32%–46%) | 31% (25%–39%) |
|
| ||||||
| No ASCT | 104 | 88 | 238 | 1.00 (ref) | 25% (18%–35%) | 18 (12%–28%) |
| ASCTb | 90 | 49 | 270 | 0.65 (0.4–1.0) | 51% (42%–69%) | 46% (37%–59%) |
Notes: All analyses adjusted for sex, age, period, educational level, number of comorbidities, cohabitation status, and primary refractory disease.
b
For ASCT, adjusted HR is calculated with ASCT as a time-dependent variable, overall survival from the day of stem cell reinfusion.
Abbreviations: ASCT, autologous stem cell transplantation; DLBCL, diffuse large B-cell lymphoma.